KM
Therapeutic Areas
Silence Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zerlasiran (SLN360) | Cardiovascular Risk Reduction (Elevated Lp(a)) | Phase 2 |
| SLN124 | Polycythemia Vera & Myeloproliferative Neoplasms | Phase 1 |
| Dapirolizumab Pegol | Systemic Lupus Erythematosus (SLE) | Phase 3 |
| AZD8233 (AstraZeneca) | Cardiovascular, Metabolic (PCSK9 target) | Phase 1 |
Leadership Team at Silence Therapeutics
CT
Craig Tooman
President and Chief Executive Officer
DH
David Horn Solomon
Chief Financial Officer
DG
Dr. Giles Campion
Senior Vice President, Head of R&D and Chief Medical Officer
DM
Dr. Mark Rothera
Former President and Chief Executive Officer
MR
Mark R. Chin
Senior Vice President, General Counsel
JH
Joanne Harrison
Senior Vice President, Human Resources
DM
Dr. Mark R. Penny
Senior Vice President, Non-Clinical Development
DM
Dr. Mark J. P. van Ool
Senior Vice President, Technical Operations